Profile And Anticoagulation Outcomes Of Patients On Warfarin Therapy In An Urban Hospital In Cape Town, South Africa

African Journal of Primary Health Care and Family Medicine

Volumn 8, Issue 1, 2021, Pages

  Sonuga, Babatunde O ^a   Hellenberg, Derek A ^a   Cupido, Clint S ^a,b   Jaeger, Cilia ^b,c  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b Department of Community Services   (South Africa)

^c DREXEL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; WARFARIN;

ADOLESCENT; ADULT; AGED; CROSS-SECTIONAL STUDY; FEMALE; HEALTH SERVICE; HOSPITAL; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PUBLIC HOSPITAL; RETROSPECTIVE STUDY; RISK FACTOR; SOUTH AFRICA; THROMBOSIS; TREATMENT OUTCOME; URBAN HEALTH; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; CROSS-SECTIONAL STUDIES; FEMALE; HOSPITALS, DISTRICT; HOSPITALS, URBAN; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SOUTH AFRICA; THROMBOSIS; TREATMENT OUTCOME; URBAN HEALTH; URBAN HEALTH SERVICES; WARFARIN; YOUNG ADULT;

EID: 85021852020     PISSN: 20712928     EISSN: 20712936     Source Type: Journal    
DOI: 10.4102/phcfm.v8i1.1032     Document Type: Article

References (42)

1. 1. ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to the global disease burden. J Thromb Haemost 2014; 12: 1580–90.
2. 2. Raskob GE, Silverton R, Bratzler DW, Heit JA, White RH. Surveillance for deep vein thrombosis and pulmonary embolism. Am J Prev Med 2010; 38: 5502–9.
3. 3. Barnes GD, Ageno W, Ansell J, Kaatz S, for the Subcommittee on the control of Anticoagulation. Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH. J Thromb Haemost 2015; 13: 1154–64.
4. 4. Cecilia Gutierrez & Daniel Blanchard. Atrial Fibrillation: Diagnosis and Treatment. Am J Fam Physician. 2011 Jan 1. 83(1): 61–68.
5. 5. Donall Forde, Mortimer B, O’Connor & Oonagh Gilligan. Potentially avoidable inpatient nights among warfarin receiving patients; an audit of a single university teaching hospital. BMC Research Notes. 2 (Mar. 13, 2009): p41.
6. 6. Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, & Ageno W. Measuring oral direct inhibitors (ODIs) of thrombotic and factor Xa: a recommendation from the subcommittee on control of anticoagulation of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis Thromb Haemost 2013; 11: 756–60.
7. 7. Dalby AJ, Wessels P & Opie LH. Warfarin in non-valvular atrial fibrillation. S Afr Med J 2013 Oct 11; 103(12); 901–4.
8. 8. Schellack N, Esterhuizen H, & Schellack G. Understanding anticoagulation therapy for stroke prevention and atrial fibrillation. S Afr Pharm J 2013 Mar 05;80(7): 13–9.
9. 9. Clarke R, Ross S, Walker T, Woods D, et al. (editors) INR testing. Best Practice Advocacy Centre. 2006 Oct.
10. 10. Glasheen J & Fugit R. Risk of over-anticoagulation with antibiotic use in outpatients on stable warfarin regimens. J Gen Intern Med.July; 20(7): 653–656.
11. 11. Njovane X & Fasinu P. Comparative utilization of warfarin in two PHCs in Cape Town. Cardiovascular J Afr 2012; 23: 901–4.
12. 12. Mortimer C, Cottrell W &Comino J Automatic drug use audit in primary care: a pilot evaluation on warfarin use in patients with atrial fibrillation. Australian J Fam Physician 2005 Oct; 34(9): 798–800.
13. 13. Hankey G Non-valvular atrial fibrillation and stroke prevention. Med J Aust 2001; 174(5): 234–239.
14. 14. Aalbers J. South Africa’s poor warfarin control raises questions of benefit above other anticoagulant therapies in atrial fibrillation. Cardiovascular J Afr. July/ August 2011; 22(4).
15. 15. Ansell J,Hirsh J, Dalen J, Bussey H, Anderson D, Poller L, Jacobson A, Deykin D, Matchar D. Management of Oral anticoagulation. American college of Chest Physicians Evidence based guidelines 2001 Jan; 119(1): 22S–38S.
16. 16. Agency for Health Care Policy and Research. Life-saving treatments to prevent stroke. Press release, September 1995. Retrieved November 1998 from the World Wide Web at http://www.ahcpr.gov/news/press/stroke.htm.
17. 17. Southern African Society of Thrombosis and Haemostasis. Guideline for Prophylactic Anticoagulation. S Afr Med J 2004Aug; 94(8): 691–695.
18. 18. Nasser S, Cecchele R, Touma S, Han P, Nair K, Vizgoft J, Murdoch V, Mullan J, & Bajorek B. Documentation of Warfarin Education provided to Hospital Patients: A Clinical Audit. Journal of Pharmacy Practice and Research; 42(2): 129–133.
19. 19. Loebstein R, Yonath H,Peleg D,Almog S, Rotenberg M,Lubetsky A,Roitelma J, Harats D, Halkin H & Ezra D. Inter-individual variability in sensitivity to warfarin-nature or nurture? Clin Pharmacol Ther 2001 Aug; 70(2):159–164.
20. 20. British Committee for Standards in Haematology (BCSH) Guidelines on oral anticoagulation: Third edition. British Journal of Haematology 1998; 101: 374–387.
21. 21. Arbring K, Uppugunduri S, & Lindahl T.: Comparison of prothrombin time (INR) results and main characteristics of patients on warfarin treatment in primary health care centres and anticoagulation clinics. BMC Health Research Services. 2013; 13:85.
22. 22. Poli D, Antonucci E, Testa S, Tosetto A, Ageno W, & Palareti G. Italian Federation of Anticoagulation Clinics: Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation. Circulation 2011; 124:824–829.
23. 23. Wieloch M, Själander A, Frykman V, Rosenqvist M, Eriksson N, & Svensson PJ: Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. Eur Heart J 2011; 32:2282–2289.
24. 24. Teklay G, Shiferaw N, and Legesse B &Bekele M. Drug-drug interactions and risk of bleeding among inpatients on warfarin therapy: a prospective observational study. Thrombosis Journal 2014; 12:20.
25. 25. Schmitt L, Speckman J & Ansell J. Quality assessment of anticoagulation dose management. Journal of thrombosis and thrombolysis 2003; 15(3): 213–216.
26. 26. Ganz L.:Up-to-date: Epidemiology of and risk factors for atrial fibrillation.
27. 27. Nguyen T; Hilmer S & Cumming R. “Review of epidemiology and management of atrial fibrillation in developing countries.” International journal of cardiology 2013 Sept; 167(6): 2412–20.
28. 28. Bristol-Myers Squibb Company. Medication Guide for Coumadin Tablets and Coumadin Injection [Package Insert]. 2010. Princeton, NJ: Bristol-Myers Squibb Company.
29. 29. Whitley HP, Fermo JD, Chumney EC, & Brzezinski WA. Effect of patient-specific factors on weekly warfarin dose. Ther Clin Risk Manag. 2007; 3:499–504. Abstract.
30. 30. Armour BS, Woollery T, Malarcher A, Pechacek TF,& Husten C. Annual smoking-attributable mortality, years of potential life lost, and productivity losses—United States, 1997–2001. Morb Mortal Wkly Rep. 2005; 54: 625–628. Medline.
31. 31. Mitchell AA. Smoking and warfarin dosage. N Engl J Med. 1972; 287:1153–1154.
32. 32. Miller LG. Recent developments in the study of the effects of cigarette smoking on clinical pharmacokinetics and clinical pharmacodynamics. Clin Pharmacokinet. 1989; 17:90–108. Abstract.
33. 33. Torn M1, Bollen WL, van der Meer FJ, van der Wall EE, & Rosendaal FR. Risks of oral anticoagulant therapy with increasing age. Arch Intern Med. 2005 Jul 11; 165(13):1527–32.
34. 34. Gasse C, Hollowell J, Meier CR, & Haefeli WE. Drug interactions and risk of acute bleeding leading to hospitalization or death in patients with chronic atrial fibrillation treated with warfarin. Throm Haemost 2005; 94(2):537–43.
35. 35. Zhang K, Young C & Berger J. Administrative claims analysis of the relationship between warfarin use and the risk of haemorrhage including drug-drug and drug-disease interaction. J Manag Care Pharm 2006; 12(8):640–48.
36. 36. Breen AB, Vaskinn TE, Reikvam A, Skovlund E, Lislevand H &, Madsen S. Warfarin treatment and bleeding. Tidsskr Nor Laegeforen 2003; 123(13):1835–7.
37. 37. Transon C, Leeman T & Dayer P. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. Eur J Clin Pharmacol 1996; 50:209–15.
38. 38. Sconce EA, Khan TI, Daly AK, Wynne HA, Kamali F. The impact of simvastatin on warfarin disposition and dose requirements. J Thromb Haemost 2006;4: 1422–4.
39. 39. University of Cape Town, Department of Pharmacology, South Africa Medicine Formulary 2008; 8th edition.
40. 40. Victoria Hospital Wynberg, Cape Town, Western Cape Anticoagulation Guideline.
41. 41. South Africa National Department of Health Essential Drug List 2012.
42. 42. Kapp PA,Klop AC, Jenkins LS. Drug interactions in primary health care in the George sub-district, South Africa: a cross sectional study. S Afr Fam Pract 2013; 55(1):78–8.